SAN LUIS OBISPO, California – April 03, 2007 – FzioMed, Inc. announced today the issuance of United States patent 7,192,984 B2 which broadens coverage for the company’s proprietary biomaterial technology in the field of aesthetic medicine.
FzioMed’s platform science involves the combination of biocompatible, absorbable polymers into innovative medical products. The new patent, entitled “Compositions of Polyacids and Polyethers and Methods for Their Use as Dermal Fillers,” covers the use of FzioMed gel formulations to make advanced dermal fillers for cosmetic tissue augmentation.
In 2006, FzioMed launched Laresse, the first ultra-smooth, non-permanent, synthetic dermal filler created from the company’s polymer technology. Laresse represents a completely new class of filler for the correction of wrinkles and lines caused by sun exposure, aging and other factors.
“We are designing a line of dermal fillers with key gel properties that offer significant advantages over the hyaluronic acid (HA) technologies being used in the market today,” said Richard Berg, Ph.D., Vice President of Research and Development and Chief Scientific Officer for FzioMed, Inc. “The new patent strengthens and expands our proprietary position around this advanced new class of fillers.”
Laresse Dermal Filler is an ultra-smooth, non-permanent, non-HA gel composed of pure, absorbable medical polymers. Laresse is the first non-permanent filler without many of the drawbacks of HA and collagen fillers. No other filler offers the same features as Laresse: non-permanent wrinkle correction, non-animal and non-bacterial components, easy injection through a very fine needle, improved comfort, and smooth texture and feel. Laresse is currently available only in the European Union.
FzioMed is a privately held medical company developing and commercializing absorbable biomaterials based on the company’s patented science. FzioMed’s polymer technology has uses in a variety of specialties including orthopedics, spine, gynecology, general surgery and aesthetic surgery. FzioMed products include Oxiplex/SP, the leading adhesion barrier for spine surgery currently marketed outside of the U.S., Oxiplex/AP adhesion barrier for gynecologic and general surgery, and Laresse dermal filler. FzioMed products are for investigational use only in the U.S.
FzioMed®, Oxiplex® and Laresse® are registered trademarks of FzioMed, Inc.